Antibody-based therapy is several steps closer to treat lethal mucormycosis
A new paper discusses the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the Mucorales fungus to invade human cells and cause mucormycosis, which has high mortality rates in people with weakened immune systems.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.